• POLICY
US-Muslim outreach:
Secretary of state Hillary Clinton has named three eminent US scientists as the nation's first science-and-technology envoys to Muslim-majority countries, where they will look to foster collaborative research programmes. The three are Bruce Alberts, editor-in-chief of Science; Elias Zerhouni, director of the US National Institutes of Health in 2002-08; and Ahmed Zewail, a Nobel laureate who serves on the President's Council of Advisors on Science and Technology.
African science: African governments could save millions of lives relatively cheaply by adopting health policies that are based on science, according to a report published on 9 November by seven of the continent's science academies. The report, which focuses on child and maternal health in sub-Saharan Africa, was unveiled at the fifth annual conference of the African Science Academy Development Initiative in Accra, Ghana. The first joint policy briefing to be produced by the initiative, it suggests that African governments are warming to the idea of taking advice from scientists. See go.nature.com/IysY5q for more. 
• BUSINESS
Clean-tech takeover: Electronics giant Panasonic attempted to catapult itself up the cleantechnology league on 5 November by launching a ¥402-billion (US$4.5 billion) bid for a majority stake in Sanyo, another Japanese electronics firm. If successful, the takeover would combine two companies that together make most of the nickel-metal hydride batteries in hybrid cars, and a sizeable proportion of the world's lithium-ion rechargeable batteries; Sanyo is also a leading solar-cell manufacturer.
SPACE LIFT MARK ONE?
For the first time, a team has won some of the prize money at NASA's Space Elevator Games, held this year on 4-6 November at the Dryden Flight Research Center in southern California. LaserMotive, a company based in Seattle, Washington, used a laser to power a solar platform (pictured, prepared by team leader David Bashford) up a 900-metre suspended cable. It whizzed at speeds of 4 metres per second, winning US$900,000. To get the whole $2 million on offer required a climb at more than 5 metres per second. Aside from a powered climber, a space elevator needs a tether that is strong, thin and light enough to reach hundreds of kilometres into space. This component of the challenge, uncontested last week, remains unmet.
went to press, the UK government said it would take steps to deal with scientists' concerns.
R&D squeeze: Pharmaceuticals firm Pfizer announced on 9 November that it would close 6 of its 20 research-anddevelopment sites and cut research at some remaining centres to leave five main hubs, following its US$67-billion acquisition of fellow drug maker Besides steroids and other general treatments for autoimmune diseases, it has been half a century since a drug was approved for systemic lupus erythematosus. Lupus affects mainly younger women, causing ailments from arthritis to kidney failure, and sometimes results in death. But last week, Human Genome Sciences (HGS), a pharmaceutical company in Rockville, Maryland, announced positive results from a second, late-stage, clinical trial of its monoclonal antibody Benlysta (belimumab), developed in partnership with drug giant GlaxoSmithKline. Benlysta specifically targets a protein that goes into overdrive in lupus, causing the body to produce antibodies that attack its own tissues.
HGS's share price rose 35% on 2 November -a single-day gain bettered only in July when its first phase III clinical trial results were announced (see chart). The news "opens the door to one of the more exciting 'new drug' stories in biotechnology in recent years. The drug defied the axiom that 'nothing ever works in lupus'", wrote Geoff Porges, an analyst at New York-based financial research firm Sanford C. Bernstein, in an investor note. Porges thinks that both the US Food and Drug Administration and the European Medicines Agency will approve the drug, and -as there are no wellplaced competitors -global revenue from Benlysta could exceed US$1.5 billion in 2012.
Monsanto in China:
The biotech seed giant Monsanto formally opened its first biotech research centre in China on 4 November, adding to similar facilities in the United States, Brazil and India. The centre, in Beijing, will concentrate on early-stage bioinformatics and genomics research and serve as a base for collaborations with Chinese scientists. The facility will focus on Monsanto's core crops of maize (corn), soya beans and cotton.
• RESEARCH 
University competition:
The UK government plans to concentrate public research funds on the nation's top few universities, according to a policy document published on 3 November. The report says that funds will be diverted towards institutions providing science and engineering degrees; researchers from different institutions might also have to collaborate, rather than compete with each other, for scarce funds, it adds.
• FUNDING Personal grants: The UK Wellcome Trust, the country's largest non-governmental funder of biomedical research, will from autumn 2010 offer longterm research grants focused on Wyeth (see Nature 457, 520-521; 2009). The company did not say how many jobs would be lost directly from these shutdowns; it has previously said it would cut 15% (around 19,500 jobs) of the combined firms' workforce.
Ginzburg (pictured below) helped to develop the Soviet hydrogen bomb in the 1940s, a project whose importance shielded him from the worst of Stalin's purges. "I was saved by the hydrogen bomb, " he said, after sharing the Nobel award for his work on the theory of superconductivity.
members of scientific advisory boards. But only 20% of research faculty received industry funding, compared with 28% in 1995, the last time a similar poll was conducted.
A. ZEMLIANICHENKO/AP SOUND BITES " The bird escaped unharmed but lost its bread. "
A statement from CERN, the European particle-physics lab near Geneva, Switzerland, on the cause of a short circuit that disrupted the Large Hadron Collider last week. An errant bird dropped a baguette on a piece of electrical equipment. See go.nature.com/mDzPFV for more.
individual scientists rather than on specific project applications. The move was in part a response to researchers' complaints about grant sizes and short funding periods. See page 144 for more.
